source
- Apple and OpenEvidence Begin Study of Experimental AI Health Chat AppApple and OpenEvidence have launched a study centered on an experimental AI-powered health chat application. The pilot allows users to link personal health data to the chatbot, which then provides…
- STAT+: FDA rejects lung cancer treatment ivonescimab from Summit TherapeuticsThe FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.STAT · 15h ago↗ source
- FDA issues complete response letter, rejecting Summit Therapeutics' ivonescimab for EGFR-mutated lung cancer